ABSTRACT
The workflow in modern hospitals entails that the medical treatment of a patient is distributed between several physicians and nurses. This leads to intensive cooperation, which takes place under particular time pressure and requires efficient conveyance of relevant patient-related medical data to colleagues. This requirement is difficult to achieve with traditional data representation approaches. In this paper, we introduce a novel concept of anatomically integrated in-place visualization designed to engage with cooperative tasks on a neurosurgical ward by using a virtual patient's body as spatial representation of visually encoded abstract medical data. Based on the findings of our field studies, we provide a set of formal requirements and procedures for this kind of visual encoding. Moreover, we implemented a prototype on a mobile device that supports the diagnosis of spinal disc herniation and has been evaluated by 10 neurosurgeons. The physicians have assessed the proposed concept as beneficial, especially emphasizing the advantages of the anatomical integration such as intuitiveness and a better data availability due to providing all information at a glance. Particularly, four of nine respondents have stressed solely benefits of the concept, other four have mentioned benefits with some limitations and only one person has seen no benefits.
Subject(s)
Hospitals , Workflow , Humans , NeurosurgeryABSTRACT
BACKGROUND: We analyzed the relationship between statin continuation or discontinuation and outcome after spontaneous intracerebral hemorrhage (ICH). METHODS: From a databank with 447 data sets, we selected patients with hypertensive or anticoagulation-related hemorrhage (volume 10-250 mL). Of 323 patients available for analysis, 63 were taking statins. This group was divided into those who discontinued (N.=18) or continued therapy (N.=45). Statin users were matched by age, sex, and National Institutes of Health Stroke Scale (NIHSS) status in 1:4 ratio to nonusers. Mortality after 30 days, 3 months, and 12 months was analyzed using Cox regression. The Glasgow Outcome Scale (GOS) scores at discharge and at least 6 months after ICH onset were recorded. RESULTS: Baseline characteristics of patients with continued and discontinued statin use were not different. Patients who discontinued statin therapy were very similar to their matched-cases; however, the control-matched cases for patients who continued statins had lower incidences of diabetes mellitus and cardiovascular diseases. In multivariate analysis, statin discontinuation was associated with a 6.9-fold (95% CI 2.09-23.13, P=0.002) higher risk of death within the first 30 days after ICH onset compared to patients who continued therapy. Patients who discontinued also had an increased risk of death within 30 days of ICH onset compared to their matched-controls (HR=3.87, 95% CI 1.69-8.87, P=0.001). The continued statin group displayed only a slight reduction in mortality risk after 3 month (HR=0.67, 95% CI 0.37-1.21, P=0.19) compared to matched-controls, but the chance to be discharge with a better neurological (NIHSS<15) was increased among patients with continued statin use (51% versus 33%, P=0.02). CONCLUSIONS: The continued use of statins after an ICH led to a small mortality reduction, whereas discontinuing statins might be related to increased mortality. Randomized clinical trials are needed to define the role of statin use in the management of acute ICH.
